Hims Found a Legal Goldmine Worth $4 Billion Hiding Behind Novo Nordisk’s Legal $450 Mistake
After getting cut off from selling knockoff versions of Ozempic by Novo Nordisk, Hims & Hers is now seizing a rare, totally legal chance to sell generic semaglutide (the magic ingredient inside Ozempic and Wegovy) in Canada. And they owe it all to one of the dumbest clerical blunders in modern pharma history.
Back in 2019, someone at Novo Nordisk forgot to pay a routine Canadian patent maintenance fee. That’s it. A fee. Not a billion-dollar lawsuit or regulatory recall… it was just a basic “click to renew” situation. Even worse, the bill was only $450 CAD. That’s less than a single month’s supply of Ozempic. Oh and it gets even funnier… Canada gave them a full year to fix it… just in case the intern in charge of “keeping billions of dollars protected” was out sick or trapped under something heavy. But Novo never paid. And unlike in the U.S., where money and lawyers can revive just about anything, Canada’s rules are crystal clear: once a patent lapses, it’s dead. Forever.
Which brings us to Hims… crashing the Canadian semaglutide market like Owen Wilson at a stranger’s wedding. Didn’t get an invite? Doesn’t matter. They showed up anyway, bottle of wine in one hand, prescription pad in the other, like, “What’s up, I heard there was cake… and also a $4 billion market opportunity.” Hims announced it plans to start selling generic semaglutide in Canada by 2026… fully approved, by the book, and without any of the legal gray zones that got them tossed from their Novo partnership earlier this year. (“Legally compliant” Hims is the new “reformed bad boy” of telehealth.) CEO Andrew Dudum called it “a major opportunity to show what affordable, high-quality weight loss care can look like.” But he really meant: “We finally found a way to sell Ozempic-style meds without getting sued into the ends of the earth.”
(Source: CNBC)
And yeah, the market’s absolutely worth swinging at. Semaglutide sales in Canada hit $1.18 billion last year and are expected to more than triple to $4.03 billion by 2035. That’s a whole lot of needles… and a whole lot of people trying to squeeze into last year’s jeans. But Hims is betting that its direct-to-consumer model will help it stand out. Of course, they’re not the only ones circling like buzzards. Sandoz and Biocon (not Bitcoin) are also filing to get in on the Canadian semaglutide action. But Hims is banking on being the cool, digitally-native disruptor.
Investors seem to be eating it up… at least for now. HIMS shares popped nearly 7% after the announcement, with analysts at Leerink calling it a smart global expansion move by “leveraging generically-available products.” But the legal cloud hasn’t totally cleared. Morgan Stanley is still sitting on a Neutral rating, citing baggage from the whole “unapproved compounded knockoff” era, not to mention Eli Lilly sharpening its knives and suing everyone within 500 feet of a GLP-1 that didn’t come straight from their labs.
Still, let’s give credit where it’s due. This time there’s no backroom compounding or any shady dealings. Just a clean, surgical strike on a billion-dollar market made possible by Novo’s $450 “oopsies” moment (someone definitely got fired). If Hims pulls this off, it could be a legit turning point. The moment they go from "those guys who sell hair pills on Instagram" to a real player in the $100B+ GLP-1 game. That’s a long way from cringey subway ads and DTC testosterone kits.
If it doesn’t? At least this time, the failure won’t come with subpoenas attached. And to think… the whole thing started because Novo Nordisk couldn’t be bothered to click “renew” on a government website. Tough look. Lucky break. Let’s see what Hims does with it.
At the time of publishing this article, Stocks.News doesn’t hold positions in companies mentioned in the article.